https://www.biopharmawatch.com/news/RARE/ultragenyx-maa-ux111-review-mhra BiopharmaWatch en 2026-11-06T08:30:00.000Z Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) https://www.biopharmawatch.com/news/PHAR/mhra-approves-pharming-joenja-treatment-children-apds BiopharmaWatch en 2026-11-06T06:00:00.000Z MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. https://www.biopharmawatch.com/news/INO/inovio-pricing-75-million-public-offering BiopharmaWatch en 2026-11-06T04:18:00.000Z INOVIO Announces Pricing of Approximately $75 Million Public Offering https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-public-offering-pricing BiopharmaWatch en 2026-11-06T03:42:00.000Z Orchestra BioMed Announces Pricing of Public Offering https://www.biopharmawatch.com/news/JNJ/fda-approval-rybrevant-faspro-head-neck-cancer BiopharmaWatch en 2026-11-06T02:03:00.000Z Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer https://www.biopharmawatch.com/news/CATX/perspective-therapeutics-bamzireotide-trial-data-nanets-2026 BiopharmaWatch en 2026-11-06T01:10:00.000Z Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs https://www.biopharmawatch.com/news/NHC/nhc-announces-common-dividend-20261106 BiopharmaWatch en 2026-11-06T01:00:00.000Z NHC Announces Common Dividend https://www.biopharmawatch.com/news/REVB/revelation-biosciences-financial-results-september-2026 BiopharmaWatch en 2026-11-05T22:29:00.000Z Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-third-quarter-earnings BiopharmaWatch en 2026-11-05T22:23:00.000Z CORRECTING and REPLACING Nu Skin Enterprises Reports Third Quarter Earnings https://www.biopharmawatch.com/news/COO/coopercompanies-release-date-fourth-quarter-full-year-2026 BiopharmaWatch en 2026-11-05T22:23:00.000Z CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2026 https://www.biopharmawatch.com/news/MRNA/moderna-mrna-influenza-covid-vaccines-authorization BiopharmaWatch en 2026-11-05T22:20:00.000Z Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-share-repurchase BiopharmaWatch en 2026-11-05T22:15:00.000Z Thermo Fisher Scientific Authorizes $5 Billion of Share Repurchases https://www.biopharmawatch.com/news/CTKB/cytek-aurora-evo-award-drug-discovery-innovation BiopharmaWatch en 2026-11-05T22:00:30.000Z Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year https://www.biopharmawatch.com/news/TMO/thermo-fisher-scientific-announces-quarterly-dividend-20261105 BiopharmaWatch en 2026-11-05T22:00:00.000Z Thermo Fisher Scientific Announces Quarterly Dividend https://www.biopharmawatch.com/news/CODX/co-diagnostics-q3-2026-earnings-release BiopharmaWatch en 2026-11-05T22:00:00.000Z Co-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and Webcast https://www.biopharmawatch.com/news/BDSX/biodesix-third-quarter-2026-results-highlights BiopharmaWatch en 2026-11-05T21:46:26.538Z Biodesix Announces Third Quarter 2026 Results and Highlights https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:46:00.465Z vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/CRIS/curis-q3-2026-results-conference-call BiopharmaWatch en 2026-11-05T21:38:00.000Z Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026 https://www.biopharmawatch.com/news/NKTX/nkarta-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:34:00.000Z Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MSLE/satellos-investor-call-update-clinical-strategy BiopharmaWatch en 2026-11-05T21:32:00.000Z Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study https://www.biopharmawatch.com/news/MTD/mettler-toledo-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:30:00.000Z Mettler-Toledo International Inc. Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/CMPS/compass-pathways-announces-new-employee-inducement-grants-nasdaq-listing-rule-20261105 BiopharmaWatch en 2026-11-05T21:30:00.000Z Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CON/concentra-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:30:00.000Z Concentra Announces Results For Its Third Quarter Ended September 30, 2026 and Raises FY 2026 Guidance https://www.biopharmawatch.com/news/BIOA/bioage-labs-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:30:00.000Z BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/TARS/tarsus-participate-upcoming-investor-conferences-20261105 BiopharmaWatch en 2026-11-05T21:30:00.000Z Tarsus to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ELUT/elutia-reports-q3-2026-results-nxt-41x-fda-submission BiopharmaWatch en 2026-11-05T21:17:00.000Z Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch https://www.biopharmawatch.com/news/ULS/uls-solutions-modernize-life-science-training BiopharmaWatch en 2026-11-05T21:15:00.000Z UL Solutions Collaborates on Cross-Industry Initiative to Modernize Life Science Regulated Training https://www.biopharmawatch.com/news/AMN/amn-healthcare-q3-2026-results BiopharmaWatch en 2026-11-05T21:15:00.000Z AMN HEALTHCARE ANNOUNCES THIRD QUARTER 2026 RESULTS https://www.biopharmawatch.com/news/CTMX/cytomx-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:15:00.000Z CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/SI/shoulder-innovations-reports-third-quarter-2026-financial-results-raises-full BiopharmaWatch en 2026-11-05T21:11:00.000Z Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook https://www.biopharmawatch.com/news/ACET/adicet-bio-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:10:00.000Z Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:10:00.000Z Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 https://www.biopharmawatch.com/news/NEPH/nephros-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:10:00.000Z Nephros Announces Strong Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-new-ceo-jeannette-bankes BiopharmaWatch en 2026-11-05T21:08:00.000Z Tandem Diabetes Care Names Jeannette Bankes as President and Chief Executive Officer https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:07:00.000Z Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-q3-2026-results-ph-762-update BiopharmaWatch en 2026-11-05T21:06:36.000Z Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation https://www.biopharmawatch.com/news/NTRA/natera-announces-leadership-transition BiopharmaWatch en 2026-11-05T21:06:00.000Z Natera Announces Leadership Transition https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-reports-q3-earnings BiopharmaWatch en 2026-11-05T21:06:00.000Z Nu Skin Enterprises Reports Third Quarter Earnings https://www.biopharmawatch.com/news/STLN/starling-oncology-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:06:00.000Z Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance https://www.biopharmawatch.com/news/RCEL/avita-medical-reports-q3-results-2026 BiopharmaWatch en 2026-11-05T21:05:58.000Z AVITA Medical Reports Third Quarter Results https://www.biopharmawatch.com/news/DH/definitive-healthcare-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:58.000Z Definitive Healthcare Reports Financial Results for Third Quarter 2026 https://www.biopharmawatch.com/news/CVRX/cvrx-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:54.000Z CVRx Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/CAMP/camp4-reports-q3-2026-results-and-highlights BiopharmaWatch en 2026-11-05T21:05:53.000Z CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:51.000Z Caribou Biosciences Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/APMD/apnimed-inc-reports-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-11-05T21:05:51.000Z Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/FOCL/focaltherics-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:50.000Z FocalTherics™ Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PROF/profound-medical-q3-2026-results-distribution-expansion BiopharmaWatch en 2026-11-05T21:05:00.000Z Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth https://www.biopharmawatch.com/news/IRTC/irhythm-holdings-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z iRhythm Holdings Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RNXT/renovorx-reports-record-q3-2026-revenue BiopharmaWatch en 2026-11-05T21:05:00.000Z RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million https://www.biopharmawatch.com/news/ABCL/abcellera-presentation-ubs-global-biopharma-conference-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026 https://www.biopharmawatch.com/news/ALEC/alector-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Alector Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PTGX/protagonist-reports-q3-2026-results-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/FLGT/fulgent-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Fulgent Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Puma Biotechnology Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PRTA/prothena-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Prothena Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TNDM/tandem-diabetes-care-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Tandem Diabetes Care Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GH/guardant-health-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-11-05T21:05:00.000Z Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NTRA/natera-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Natera Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments https://www.biopharmawatch.com/news/NUS/nu-skin-enterprises-announces-quarterly-dividend-20261105 BiopharmaWatch en 2026-11-05T21:05:00.000Z Nu Skin Enterprises Announces Quarterly Dividend https://www.biopharmawatch.com/news/INGN/inogen-announces-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Inogen Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DNA/ginkgo-bioworks-q3-2026-results-autonomous-lab-sale BiopharmaWatch en 2026-11-05T21:05:00.000Z Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Guardian Pharmacy Services Reports Third Quarter 2026 Financial Results; Raises Full-Year Guidance https://www.biopharmawatch.com/news/ASTH/astrana-health-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Astrana Health, Inc. Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/SOLV/solventum-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Solventum Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TXG/10x-genomics-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z 10x Genomics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Castle Biosciences Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/CYRX/cryoport-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Cryoport Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HALO/halozyme-reports-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:05:00.000Z HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-05T21:05:00.000Z Tyra Biosciences to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AORT/artivion-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Artivion Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NUTX/nutex-health-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z NUTEX HEALTH REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/SGHT/sight-sciences-investor-conferences-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Sight Sciences to Present at Two Upcoming Investor Conferences https://www.biopharmawatch.com/news/EQ/equillium-participate-investor-conferences BiopharmaWatch en 2026-11-05T21:05:00.000Z Equillium to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-inducement-grant-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-11-05T21:05:00.000Z Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MDWD/mediwound-closes-17-25-million-offering BiopharmaWatch en 2026-11-05T21:05:00.000Z MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/RZLT/rezolute-q1-fiscal-2027-results-business-update BiopharmaWatch en 2026-11-05T21:05:00.000Z Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ICUI/icu-medical-q3-2026-results-guidance BiopharmaWatch en 2026-11-05T21:05:00.000Z ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range https://www.biopharmawatch.com/news/SANA/sana-biotechnology-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/NYXH/nyxoah-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Nyxoah Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/MOBI/mobia-medical-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Mobia Medical Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MGNX/macrogenics-participate-investor-conferences-november BiopharmaWatch en 2026-11-05T21:05:00.000Z MacroGenics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-guggenheim-healthcare-conference-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-nomlabofusp-icar-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ORGO/organogenesis-holdings-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:05:00.000Z Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-positive-data-liver-meeting-2026 BiopharmaWatch en 2026-11-05T21:05:00.000Z Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026 https://www.biopharmawatch.com/news/HCAT/health-catalyst-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:03:47.000Z Health Catalyst Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/SINT/sintx-reports-third-quarter-2026-revenue-growth BiopharmaWatch en 2026-11-05T21:02:29.000Z SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization https://www.biopharmawatch.com/news/KYTX/kyverna-therapeutics-jefferies-conference-2026 BiopharmaWatch en 2026-11-05T21:02:27.000Z Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference https://www.biopharmawatch.com/news/KROS/keros-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T21:02:08.000Z Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SPRY/ars-pharma-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:02:01.000Z ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-05T21:02:00.000Z Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/JANX/janux-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T21:02:00.000Z Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TMDX/transmedics-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-05T21:02:00.000Z TransMedics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OMDA/omada-health-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:02:00.000Z Omada Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/GMED/globus-medical-third-quarter-2026-results BiopharmaWatch en 2026-11-05T21:02:00.000Z Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program https://www.biopharmawatch.com/news/CLDX/celldex-reports-third-quarter-results-corporate-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Celldex Reports Third Quarter Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ACH/accendra-health-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Accendra Health Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-q3-2026-results-pipeline-progress BiopharmaWatch en 2026-11-05T21:01:00.000Z Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress https://www.biopharmawatch.com/news/NGNE/neurogene-announces-inducement-grant-nasdaq-listing-rule-5635-c-4 BiopharmaWatch en 2026-11-05T21:01:00.000Z Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates https://www.biopharmawatch.com/news/INO/inovio-proposed-public-offering-common-stock BiopharmaWatch en 2026-11-05T21:01:00.000Z INOVIO Announces Proposed Public Offering of its Common Stock https://www.biopharmawatch.com/news/RIGL/rigel-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Rigel Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-et-700-pilot-study-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability https://www.biopharmawatch.com/news/ATYR/atyr-pharma-third-quarter-2026-results-update BiopharmaWatch en 2026-11-05T21:01:00.000Z aTyr Pharma Announces Third Quarter 2026 Results and Provides Corporate Update https://www.biopharmawatch.com/news/VYGR/voyager-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Voyager Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/MNKD/mannkind-q3-2026-financial-results-business-update BiopharmaWatch en 2026-11-05T21:01:00.000Z MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-announces-public-offering BiopharmaWatch en 2026-11-05T21:01:00.000Z Orchestra BioMed Announces Proposed Public Offering https://www.biopharmawatch.com/news/CELC/celcuity-reports-q3-2026-results-and-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261105 BiopharmaWatch en 2026-11-05T21:01:00.000Z Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/COGT/cogent-biosciences-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q3-2026 BiopharmaWatch en 2026-11-05T21:01:00.000Z Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/INAB/in8bio-reports-q3-2026-results-and-highlights BiopharmaWatch en 2026-11-05T21:01:00.000Z IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/VERA/vera-therapeutics-business-update-q3-2026 BiopharmaWatch en 2026-11-05T21:01:00.000Z Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/XRAY/dentsply-sirona-reports-q3-2026-results BiopharmaWatch en 2026-11-05T21:01:00.000Z Dentsply Sirona Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/ASND/ascendis-report-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:01:00.000Z Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 https://www.biopharmawatch.com/news/INGN/inogen-announces-leadership-transition BiopharmaWatch en 2026-11-05T21:00:00.000Z Inogen Announces Leadership Transition https://www.biopharmawatch.com/news/INMB/inmune-bio-q3-2026-results-business-update BiopharmaWatch en 2026-11-05T21:00:00.000Z INmune Bio Inc. Announces Third Quarter 2026 Results and Provides Business Update https://www.biopharmawatch.com/news/TLSA/tiziana-host-investor-call-inform-ms-results BiopharmaWatch en 2026-11-05T19:00:00.000Z Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results https://www.biopharmawatch.com/news/GMAB/genmab-financial-results-nine-months-2026 BiopharmaWatch en 2026-11-05T16:02:00.000Z Genmab Announces Financial Results for the Nine Months of 2026 https://www.biopharmawatch.com/news/BIIB/biogen-update-private-payer-coverage-zurzuvae BiopharmaWatch en 2026-11-05T16:00:00.000Z Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone) https://www.biopharmawatch.com/news/IGC/igc-pharma-alzheimers-agitation-drug-patented BiopharmaWatch en 2026-11-05T15:18:00.000Z IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears https://www.biopharmawatch.com/news/NVO/novo-nordisk-share-trading-disclosure BiopharmaWatch en 2026-11-05T15:02:00.000Z Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons https://www.biopharmawatch.com/news/MDGL/madrigal-rezdiffra-real-world-data-aasld-2026 BiopharmaWatch en 2026-11-05T15:00:00.000Z Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra https://www.biopharmawatch.com/news/ALT/altimmune-reclaim-phase-2-trial-pemvidutide-aasld-2026 BiopharmaWatch en 2026-11-05T15:00:00.000Z Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026 https://www.biopharmawatch.com/news/VIR/vir-biotechnology-eclipse-1-data-presentation BiopharmaWatch en 2026-11-05T15:00:00.000Z Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call https://www.biopharmawatch.com/news/GILD/gilead-phase-3-ideal-study-results-livdelzi BiopharmaWatch en 2026-11-05T15:00:00.000Z Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC) https://www.biopharmawatch.com/news/VSEE/vsee-health-new-hospital-agreements BiopharmaWatch en 2026-11-05T14:30:00.000Z VSee Health Announces 13 New Hospital Agreements Expected to Generate More Than $3 Million in Annual Revenue https://www.biopharmawatch.com/news/MMSI/merit-medical-avf-cohort-wrap-global-registry BiopharmaWatch en 2026-11-05T14:25:00.000Z Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry https://www.biopharmawatch.com/news/KAPA/kairos-pharma-biotech-breakthrough-award-oncology BiopharmaWatch en 2026-11-05T14:15:00.000Z Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology https://www.biopharmawatch.com/news/AIM/aim-immunotech-ampligen-ras-targeted-therapies BiopharmaWatch en 2026-11-05T14:13:00.000Z AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer https://www.biopharmawatch.com/news/SNWV/sanuwave-health-comments-2027-medicare-rate-ultramist BiopharmaWatch en 2026-11-05T14:08:00.000Z Sanuwave Health Comments on 2027 Medicare Physician Fee Schedule Rate for Ultramist https://www.biopharmawatch.com/news/NTHI/neonc-reports-q3-2026-results-and-clinical-progress BiopharmaWatch en 2026-11-05T14:00:16.000Z NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress https://www.biopharmawatch.com/news/AMGN/repatha-lowers-heart-attack-risk-study BiopharmaWatch en 2026-11-05T14:00:00.000Z REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY https://www.biopharmawatch.com/news/HIMS/hims-hers-benefits-new-partners-health-support BiopharmaWatch en 2026-11-05T14:00:00.000Z Hims & Hers Benefits Adds Grüns, Medjet, Tonal, and Viome for Whole-Body Health and Support When You Need It Most https://www.biopharmawatch.com/news/SBC/shonan-beauty-clinic-newsweek-medical-tourism-2027 BiopharmaWatch en 2026-11-05T14:00:00.000Z Shonan Beauty Clinic Named to Newsweek’s “World’s Best Hospitals & Clinics for Medical Tourism 2027” https://www.biopharmawatch.com/news/ZLAB/zai-lab-zocilurtatug-pelitecan-update BiopharmaWatch en 2026-11-05T14:00:00.000Z Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas https://www.biopharmawatch.com/news/CODX/co-diagnostics-participate-global-tuberculosis-events BiopharmaWatch en 2026-11-05T14:00:00.000Z Co-Diagnostics to Participate in Three Global Tuberculosis Events in November as CoSara Advances Toward Anticipated India Launch https://www.biopharmawatch.com/news/POCI/precision-optics-2-million-follow-on-order BiopharmaWatch en 2026-11-05T14:00:00.000Z Precision Optics Announces $2 Million Follow-On Order from Existing Top-Tier Aerospace Customer https://www.biopharmawatch.com/news/IVF/invo-fertility-patientfi-affordable-treatment BiopharmaWatch en 2026-11-05T14:00:00.000Z INVO Fertility Partners with PatientFi to Help Make Fertility Treatment More Affordable https://www.biopharmawatch.com/news/MTVA/metavia-da-1726-phase-1-results BiopharmaWatch en 2026-11-05T13:55:00.000Z MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data https://www.biopharmawatch.com/news/DMAC/diamedica-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-05T13:45:00.000Z DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026 https://www.biopharmawatch.com/news/HCWB/hcw-biologics-secures-debt-financing BiopharmaWatch en 2026-11-05T13:45:00.000Z HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing https://www.biopharmawatch.com/news/PRE/care-bears-prenetics-global-partnership BiopharmaWatch en 2026-11-05T13:32:00.000Z Care Bears And Prenetics' IM8 Announce Global Partnership https://www.biopharmawatch.com/news/AIDX/vote-2020-biolabs-special-meeting-december-2026 BiopharmaWatch en 2026-11-05T13:31:00.000Z REMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026 https://www.biopharmawatch.com/news/PRE/prenetics-authentic-brands-care-bears-partnership BiopharmaWatch en 2026-11-05T13:30:37.000Z Prenetics’ IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics https://www.biopharmawatch.com/news/DRMA/dermata-therapeutics-tome-skincare-launch-media-coverage BiopharmaWatch en 2026-11-05T13:30:00.000Z Dermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial Launch https://www.biopharmawatch.com/news/APVO/aptevos-mipletamig-reduces-infusion-reactions-aml BiopharmaWatch en 2026-11-05T13:30:00.000Z Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML https://www.biopharmawatch.com/news/QTI/qt-imaging-presents-canaccord-genuity-forum BiopharmaWatch en 2026-11-05T13:30:00.000Z QT Imaging to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum https://www.biopharmawatch.com/news/MIRM/genedx-mirum-sponsored-testing-programs BiopharmaWatch en 2026-11-05T13:30:00.000Z GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing https://www.biopharmawatch.com/news/TMO/thermo-fisher-introduces-value-priced-qpcr-master-mixes BiopharmaWatch en 2026-11-05T13:30:00.000Z Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance https://www.biopharmawatch.com/news/FBLG/fibrobiologics-european-patent-fibroblast-delivery BiopharmaWatch en 2026-11-05T13:30:00.000Z FibroBiologics Announces Grant of European Patent for Fibroblast Delivery of Tumor Inhibitory Agents https://www.biopharmawatch.com/news/NBIX/neurocrine-ingrezza-survey-results-tardive-dyskinesia BiopharmaWatch en 2026-11-05T13:30:00.000Z Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules https://www.biopharmawatch.com/news/LSTA/marea-therapeutics-upcoming-investor-conferences BiopharmaWatch en 2026-11-05T13:30:00.000Z Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences https://www.biopharmawatch.com/news/MBOT/microbot-medical-ip-portfolio-expansion BiopharmaWatch en 2026-11-05T13:30:00.000Z Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion https://www.biopharmawatch.com/news/QNRX/quoin-pharmaceuticals-provides-corporate-update-reports-third-quarter-2026-financial BiopharmaWatch en 2026-11-05T13:30:00.000Z Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IRON/disc-medicine-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T13:30:00.000Z Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T13:30:00.000Z Dogwood Therapeutics Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DERM/journey-medical-q3-2026-financial-results-announcement BiopharmaWatch en 2026-11-05T13:30:00.000Z Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/EYE/americas-best-flagship-store-alpharetta BiopharmaWatch en 2026-11-05T13:27:00.000Z America's Best Opens Flagship Store Built Around One Connected Experience https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-best-place-to-work-2026 BiopharmaWatch en 2026-11-05T13:25:00.000Z Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year https://www.biopharmawatch.com/news/SCYX/scynexis-reports-q3-2026-results-and-update BiopharmaWatch en 2026-11-05T13:20:00.000Z SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ANVS/annovis-pricing-21-million-public-offering BiopharmaWatch en 2026-11-05T13:05:00.000Z Annovis Announces Pricing of $21.0 Million Public Offering https://www.biopharmawatch.com/news/RTSN/retension-pharmaceuticals-guggenheim-conference-2026 BiopharmaWatch en 2026-11-05T13:02:00.000Z Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/LABT/lakewood-amedex-redemption-series-c-preferred-stock BiopharmaWatch en 2026-11-05T13:02:00.000Z Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption https://www.biopharmawatch.com/news/ARQT/arcutis-phase-3-study-zoryve-atopic-dermatitis BiopharmaWatch en 2026-11-05T13:00:24.000Z Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis https://www.biopharmawatch.com/news/ARQT/arcutis-phase-3-study-zoryve-cream-atopic-dermatitis BiopharmaWatch en 2026-11-05T13:00:24.000Z Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis https://www.biopharmawatch.com/news/OSTX/os-therapies-phase-2b-herlystic-drug-substance-requalification BiopharmaWatch en 2026-11-05T13:00:00.000Z OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-investor-conferences-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Processa Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ALT/altimmune-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-05T13:00:00.000Z Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 https://www.biopharmawatch.com/news/COSM/cosmos-health-cosmo-farm-automated-infrastructure BiopharmaWatch en 2026-11-05T13:00:00.000Z Cosmos Health's CosmoFarm Begins Commissioning New Automated Order-Processing and Vehicle-Loading Infrastructure, Advancing Capacity That Could Support Over $120 Million in Annual Revenue https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-q3-2026-report BiopharmaWatch en 2026-11-05T13:00:00.000Z Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 https://www.biopharmawatch.com/news/OGN/organon-vtama-analysis-acaa-meeting-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting https://www.biopharmawatch.com/news/ICLR/icon-firecrest-ai-video-engine-launch BiopharmaWatch en 2026-11-05T13:00:00.000Z ICON Launches FIRECREST AI-Directed Video Engine, Changing the Economics of Site Communications https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-gx-03-award-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Turn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-fda-phase-3-edg-7500-hcm BiopharmaWatch en 2026-11-05T13:00:00.000Z Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring https://www.biopharmawatch.com/news/MMED/minimed-participate-upcoming-investor-conferences-20261105 BiopharmaWatch en 2026-11-05T13:00:00.000Z MiniMed to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/SCNI/scinai-reports-revenue-growth-cdmo-expansion BiopharmaWatch en 2026-11-05T13:00:00.000Z Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands https://www.biopharmawatch.com/news/NVAX/novavax-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T13:00:00.000Z Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/LPCN/lipocine-financial-results-q3-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Lipocine Announces Financial Results for the Third Quarter of 2026 https://www.biopharmawatch.com/news/GALT/galectin-therapeutics-belapectin-aasld-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026 https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-05T13:00:00.000Z Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T13:00:00.000Z Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/ECOR/electrocore-participate-canaccord-genuity-medtech-diagnostics-digital-health-services BiopharmaWatch en 2026-11-05T13:00:00.000Z electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-investor-conferences-november BiopharmaWatch en 2026-11-05T13:00:00.000Z Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/IMMP/immutep-poster-presentations-ctos-esmo-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026 https://www.biopharmawatch.com/news/BDMD/baird-medical-alpmed-fda-ce-submissions-ire-system BiopharmaWatch en 2026-11-05T13:00:00.000Z Baird Medical and Alpmed Announce FDA 510(k) and EU CE Submissions for Irreversible Electroporation (IRE) System https://www.biopharmawatch.com/news/STTK/shattuck-labs-q3-2026-results-business-highlights BiopharmaWatch en 2026-11-05T13:00:00.000Z Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/SCTX/scribe-therapeutics-participate-upcoming-healthcare-investor-conferences BiopharmaWatch en 2026-11-05T13:00:00.000Z Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-q3-2026-results-update BiopharmaWatch en 2026-11-05T13:00:00.000Z Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-05T13:00:00.000Z Ovid Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/SGP/spyglass-pharma-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-05T13:00:00.000Z SpyGlass Pharma to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/TSHA/taysha-gene-therapies-q3-2026-results-conference-call BiopharmaWatch en 2026-11-05T13:00:00.000Z Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12 https://www.biopharmawatch.com/news/SLDB/solid-biosciences-guggenheim-healthcare-conference BiopharmaWatch en 2026-11-05T13:00:00.000Z Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/SGHT/cms-establishes-supply-code-tearcare-smartlids BiopharmaWatch en 2026-11-05T13:00:00.000Z Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids https://www.biopharmawatch.com/news/BLTE/belite-bio-webcast-november-2026-financial-results BiopharmaWatch en 2026-11-05T13:00:00.000Z Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-november-2026-events BiopharmaWatch en 2026-11-05T13:00:00.000Z Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026 https://www.biopharmawatch.com/news/VCEL/vericel-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:55:00.000Z Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance https://www.biopharmawatch.com/news/INTS/intensity-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-05T12:45:00.000Z Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/RCEL/avitamedical-medicare-payment-framework-recell-2027 BiopharmaWatch en 2026-11-05T12:45:00.000Z AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027 https://www.biopharmawatch.com/news/SABS/sab-bio-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:30:49.000Z SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/AGL/agilon-health-virtual-investor-event-november-2026 BiopharmaWatch en 2026-11-05T12:30:00.000Z agilon health to Host Virtual Investor Event “Driving Performance At Scale: The agilon Framework” on November 17, 2026 https://www.biopharmawatch.com/news/AGEN/agenus-reports-q3-2026-results-bot-bal-marketing-authorizations BiopharmaWatch en 2026-11-05T12:30:00.000Z Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study https://www.biopharmawatch.com/news/SNDA/sonida-senior-living-q3-2026-results BiopharmaWatch en 2026-11-05T12:30:00.000Z Sonida Senior Living Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/BHVN/biohaven-graves-disease-research-phase-3-trial-bhv-1300 BiopharmaWatch en 2026-11-05T12:30:00.000Z Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-05T12:30:00.000Z Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/LFMD/life-md-expands-access-lilly-glp-1-medicines BiopharmaWatch en 2026-11-05T12:30:00.000Z LifeMD expands access to Lilly’s self-pay GLP-1 medicines, enabling option to dispense and ship directly to patients nationwide https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:30:00.000Z Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/CRON/cronos-group-reports-q3-2026-results BiopharmaWatch en 2026-11-05T12:30:00.000Z Cronos Group Reports 2026 Third Quarter Results https://www.biopharmawatch.com/news/MDCX/medicus-pharma-present-bio-europe-2026 BiopharmaWatch en 2026-11-05T12:30:00.000Z Medicus Pharma to Present at BIO-Europe 2026 https://www.biopharmawatch.com/news/COLL/collegium-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:30:00.000Z Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance https://www.biopharmawatch.com/news/CABA/cabaletta-bio-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T12:30:00.000Z Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LNTH/lantheus-welcomes-cms-cy27-final-rule-advancing-access-diagnostic-radiopharmaceuticals BiopharmaWatch en 2026-11-05T12:15:00.000Z Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals https://www.biopharmawatch.com/news/LNTH/lantheus-cms-cy27-final-rule-diagnostic-radiopharmaceuticals BiopharmaWatch en 2026-11-05T12:15:00.000Z Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals https://www.biopharmawatch.com/news/DTIL/precision-biosciences-pricing-offering-common-stock BiopharmaWatch en 2026-11-05T12:10:00.000Z Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:10:00.000Z Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/ACB/aurora-cannabis-fiscal-2027-q2-results BiopharmaWatch en 2026-11-05T12:05:00.000Z Aurora Cannabis Announces Fiscal 2027 Second Quarter Results https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-raises-2026-guidance BiopharmaWatch en 2026-11-05T12:05:00.000Z Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance https://www.biopharmawatch.com/news/RGNX/regenxbio-reports-q3-2026-results BiopharmaWatch en 2026-11-05T12:05:00.000Z REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/SEER/seer-victory-itc-patent-dispute-nanomics BiopharmaWatch en 2026-11-05T12:00:37.000Z Seer Secures Key Victory in ITC Patent Dispute as Investigative Staff Backs All Requested Remedies Against Nanomics https://www.biopharmawatch.com/news/KRSA/korsana-biosciences-q3-2026-results-update BiopharmaWatch en 2026-11-05T12:00:33.000Z Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-reports-q3-2026-results-micvo-progress BiopharmaWatch en 2026-11-05T12:00:30.000Z Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO) https://www.biopharmawatch.com/news/COCH/envoy-medical-q3-2026-results-progress BiopharmaWatch en 2026-11-05T12:00:00.000Z Envoy Medical Reports Third Quarter 2026 Results and Highlights Continued Progress https://www.biopharmawatch.com/news/GANX/gain-therapeutics-late-breakers-poster-presentations BiopharmaWatch en 2026-11-05T12:00:00.000Z Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences https://www.biopharmawatch.com/news/AKBA/akebia-vocal-trial-positive-results-vadadustat BiopharmaWatch en 2026-11-05T12:00:00.000Z Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/XERS/xeris-biopharma-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/DTIL/precision-biosciences-positive-dsmb-review-pbgene-dmd BiopharmaWatch en 2026-11-05T12:00:00.000Z Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study https://www.biopharmawatch.com/news/DTIL/precision-biosciences-pbgene-hbv-data-aasld-2026 BiopharmaWatch en 2026-11-05T12:00:00.000Z Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure https://www.biopharmawatch.com/news/ALKS/alkermes-research-neuroscience-education-institute-fall-congress BiopharmaWatch en 2026-11-05T12:00:00.000Z Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress https://www.biopharmawatch.com/news/ZTS/zoetis-third-quarter-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance https://www.biopharmawatch.com/news/NTRA/signatera-monitoring-immunotherapy-ctdna-clearance-survival BiopharmaWatch en 2026-11-05T12:00:00.000Z Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers https://www.biopharmawatch.com/news/EVH/evolent-announces-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Evolent Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/GNPX/genprex-reqorsa-gene-therapy-aging-resilience BiopharmaWatch en 2026-11-05T12:00:00.000Z Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress https://www.biopharmawatch.com/news/EVGN/evogene-q3-2026-financial-results-release BiopharmaWatch en 2026-11-05T12:00:00.000Z Evogene Schedules Third Quarter 2026 Financial Results Release https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-acaa-meeting-2026 BiopharmaWatch en 2026-11-05T12:00:00.000Z Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-bexobrutideg-phase-1a-1b-trial-data BiopharmaWatch en 2026-11-05T12:00:00.000Z Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition https://www.biopharmawatch.com/news/APYX/apyx-medical-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Apyx Medical Corporation Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KRRO/korro-reports-q3-2026-results-and-update BiopharmaWatch en 2026-11-05T12:00:00.000Z Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T12:00:00.000Z Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/LNTH/lantheus-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Lantheus Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q3-2026-revenue-report BiopharmaWatch en 2026-11-05T12:00:00.000Z Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates https://www.biopharmawatch.com/news/IMDX/imdx-third-quarter-results-november-2026 BiopharmaWatch en 2026-11-05T12:00:00.000Z iMDx to Release Third Quarter Results on November 16, 2026 https://www.biopharmawatch.com/news/AVTX/avalotherapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T12:00:00.000Z Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/EYPT/eyepoint-report-q3-2026-results-november-12 BiopharmaWatch en 2026-11-05T12:00:00.000Z EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/CLYM/climb-bio-q3-2026-financial-results-updates BiopharmaWatch en 2026-11-05T12:00:00.000Z Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-q3-2026-results-updates BiopharmaWatch en 2026-11-05T12:00:00.000Z Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates https://www.biopharmawatch.com/news/OKYO/okyo-pharma-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-05T12:00:00.000Z OKYO Pharma to Present at the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-05T12:00:00.000Z Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/FATE/fate-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/MCTA/charming-medical-nasdaq-delisting-notice BiopharmaWatch en 2026-11-05T12:00:00.000Z Charming Medical Limited Announces Receipt of Nasdaq Delisting Determination Notice. https://www.biopharmawatch.com/news/TRDA/entrada-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Entrada Therapeutics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T12:00:00.000Z Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/PMN/promis-neurosciences-november-conferences-2026 BiopharmaWatch en 2026-11-05T12:00:00.000Z ProMIS Neurosciences to Participate in Upcoming Conferences in November https://www.biopharmawatch.com/news/IRD/opus-genetics-phase-1-2-trial-opgx-best1 BiopharmaWatch en 2026-11-05T12:00:00.000Z Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-drug-discovery-award-2026 BiopharmaWatch en 2026-11-05T12:00:00.000Z Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards https://www.biopharmawatch.com/news/VTRS/viatris-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-05T11:59:00.000Z Viatris Reports Third-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-05T11:59:00.000Z Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-05T11:51:00.000Z ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/LTGO/latigo-biotherapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T11:47:00.000Z Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/LLY/lilly-showcase-new-retatrutide-taltz-ixekizumab-zepbound-tirzepatide-data-acr BiopharmaWatch en 2026-11-05T11:45:00.000Z Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity https://www.biopharmawatch.com/news/LLY/lilly-retatrutide-taltz-zepbound-acr-convergence-2026 BiopharmaWatch en 2026-11-05T11:45:00.000Z Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity https://www.biopharmawatch.com/news/WRBY/warby-parker-q3-2026-results BiopharmaWatch en 2026-11-05T11:45:00.000Z Warby Parker Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/TFX/teleflex-announces-quarterly-dividend-20261105 BiopharmaWatch en 2026-11-05T11:45:00.000Z Teleflex Announces Quarterly Dividend https://www.biopharmawatch.com/news/CAH/cardinal-health-q1-fy2027-results-outlook BiopharmaWatch en 2026-11-05T11:45:00.000Z Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook https://www.biopharmawatch.com/news/LTGO/latigo-biotherapeutics-ceo-transition-growth BiopharmaWatch en 2026-11-05T11:45:00.000Z Latigo Biotherapeutics Announces CEO Transition to Support the Company’s Next Phase of Growth https://www.biopharmawatch.com/news/BDX/bd-reports-fourth-quarter-fiscal-2026-results BiopharmaWatch en 2026-11-05T11:30:00.000Z BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results https://www.biopharmawatch.com/news/EVMN/evommune-webcast-evo570-immunology-portfolio BiopharmaWatch en 2026-11-05T11:30:00.000Z Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET https://www.biopharmawatch.com/news/TFX/teleflex-third-quarter-results-2026 BiopharmaWatch en 2026-11-05T11:30:00.000Z Teleflex Reports Third Quarter Financial Results and Full Year 2026 Outlook https://www.biopharmawatch.com/news/ZLAB/zai-lab-q3-2026-financial-results BiopharmaWatch en 2026-11-05T11:30:00.000Z Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates https://www.biopharmawatch.com/news/INFU/infusystem-financial-results-q3-2026 BiopharmaWatch en 2026-11-05T11:30:00.000Z InfuSystem Announces Financial Results for Third Quarter 2026 https://www.biopharmawatch.com/news/HSIC/henry-schein-investor-conferences-november-december BiopharmaWatch en 2026-11-05T11:30:00.000Z Henry Schein to Participate in Upcoming Investor Conferences in November and December https://www.biopharmawatch.com/news/AGIO/agios-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-05T11:30:00.000Z Agios Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/BDX/bdx-dividend-increase-share-repurchase-2026 BiopharmaWatch en 2026-11-05T11:25:00.000Z BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases https://www.biopharmawatch.com/news/TRLV/trulieve-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-05T11:15:00.000Z Trulieve Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/PBH/prestige-consumer-healthcare-inc-reports-fiscal-2027-second-quarter-results BiopharmaWatch en 2026-11-05T11:00:00.000Z Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results https://www.biopharmawatch.com/news/ONC/beone-medicines-q3-2026-financial-results BiopharmaWatch en 2026-11-05T11:00:00.000Z BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/OSCR/oscar-health-q3-2026-results-outlook BiopharmaWatch en 2026-11-05T11:00:00.000Z Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full Year 2026 Outlook https://www.biopharmawatch.com/news/HAE/haemonetics-q2-fiscal-2027-results BiopharmaWatch en 2026-11-05T11:00:00.000Z Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website https://www.biopharmawatch.com/news/LFST/lifestance-reports-strong-q3-2026-results BiopharmaWatch en 2026-11-05T11:00:00.000Z LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook https://www.biopharmawatch.com/news/CGTX/cognition-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-05T11:00:00.000Z Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update https://www.biopharmawatch.com/news/PRVA/privia-health-reports-strong-q3-2026-results BiopharmaWatch en 2026-11-05T11:00:00.000Z Privia Health Reports Strong Third Quarter and Year-to-Date 2026 Results https://www.biopharmawatch.com/news/ENOV/enovis-third-quarter-2026-results BiopharmaWatch en 2026-11-05T11:00:00.000Z ENOVIS Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/VCRE/vicore-pharma-q3-2026-financial-results-update BiopharmaWatch en 2026-11-05T07:20:00.000Z Vicore Pharma Announces Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/EVO/evotec-q3-2026-results-growth-momentum BiopharmaWatch en 2026-11-05T07:18:00.000Z Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-acquires-egetis-therapeutics BiopharmaWatch en 2026-11-05T06:33:00.000Z ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business https://www.biopharmawatch.com/news/MOLN/molecular-partners-present-mp0712-2026-conferences BiopharmaWatch en 2026-11-05T06:00:28.000Z Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026 https://www.biopharmawatch.com/news/IPHA/innate-pharma-q3-2026-update BiopharmaWatch en 2026-11-05T05:00:00.000Z Innate Pharma Reports Third Quarter 2026 Business and Financial Update https://www.biopharmawatch.com/news/MESO/ryoncil-first-line-treatment-pediatric-gvhd BiopharmaWatch en 2026-11-05T00:11:00.000Z Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar https://www.biopharmawatch.com/news/ABT/abbott-novo-partnership-launch-plosbrio-semaglutide BiopharmaWatch en 2026-11-05T00:00:00.000Z Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific https://www.biopharmawatch.com/news/HCM/hutchmed-sovleplenib-fda-orphan-drug-designation-aiha BiopharmaWatch en 2026-11-05T00:00:00.000Z HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-ash-2026-presentation-data BiopharmaWatch en 2026-11-04T23:30:00.000Z Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026 https://www.biopharmawatch.com/news/IMRN/immuron-revenue-growth-report-november-2026 BiopharmaWatch en 2026-11-04T23:10:00.000Z Emerging Growth Research Reports Continued Revenue Growth at Immuron https://www.biopharmawatch.com/news/ALNY/alnylam-1-billion-share-repurchase-leadership-change BiopharmaWatch en 2026-11-04T22:15:00.000Z Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership https://www.biopharmawatch.com/news/EVMN/evommune-announces-30-million-private-placement BiopharmaWatch en 2026-11-04T22:10:00.000Z Evommune Announces $30 Million Private Placement https://www.biopharmawatch.com/blog/biotech-anatomy-2026 BiopharmaWatch en 2026-11-04T22:06:48.952Z Biotech Anatomy 2026: What 1,640 Readouts Really Paid https://www.biopharmawatch.com/news/EVMN/evommune-license-evo570-hinova-pharmaceuticals BiopharmaWatch en 2026-11-04T22:02:00.000Z Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals https://www.biopharmawatch.com/news/VMD/viemed-healthcare-q3-2026-financial-results BiopharmaWatch en 2026-11-04T22:00:00.000Z Viemed Healthcare Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-reports-inducement-awards-nasdaq-listing-rule-5635-c-20261104 BiopharmaWatch en 2026-11-04T22:00:00.000Z Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/INM/inmed-announces-results-2026-annual-meeting BiopharmaWatch en 2026-11-04T21:51:00.000Z InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T21:36:00.000Z Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 https://www.biopharmawatch.com/news/NHC/national-healthcare-properties-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:35:00.000Z National Healthcare Properties Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/FOCL/focaltherics-investor-conferences-2026 BiopharmaWatch en 2026-11-04T21:30:49.000Z FocalTherics™ to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/FOCL/focaltherics-participate-investor-conferences BiopharmaWatch en 2026-11-04T21:30:49.000Z FocalTherics™ to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ACRV/acrivon-presents-eortc-nci-aacr-symposium-2026 BiopharmaWatch en 2026-11-04T21:30:39.000Z Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics https://www.biopharmawatch.com/news/ACRV/acrivon-presentation-eortc-nci-aacr-symposium-2026 BiopharmaWatch en 2026-11-04T21:30:39.000Z Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics https://www.biopharmawatch.com/news/MSA/msa-safety-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T21:30:00.000Z MSA Safety to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/STIM/neuronetics-reports-inducement-grant-nasdaq-listing-rule-5635-c-4 BiopharmaWatch en 2026-11-04T21:30:00.000Z Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/STE/steris-fiscal-2027-q2-financial-results BiopharmaWatch en 2026-11-04T21:30:00.000Z STERIS Announces Financial Results for Fiscal 2027 Second Quarter https://www.biopharmawatch.com/news/EDSA/edesa-biotech-guggenheim-healthcare-conference-2026 BiopharmaWatch en 2026-11-04T21:30:00.000Z Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-2026-jefferies-conference BiopharmaWatch en 2026-11-04T21:30:00.000Z Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/OPK/opko-health-q3-2026-results BiopharmaWatch en 2026-11-04T21:23:00.000Z OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-reports-q1-results BiopharmaWatch en 2026-11-04T21:22:00.000Z Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance https://www.biopharmawatch.com/news/ARAY/accuray-reverse-stock-split-november-2026 BiopharmaWatch en 2026-11-04T21:20:00.000Z Accuray Announces 1-for-40 Reverse Stock Split https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-q3-2026-financial-results-update BiopharmaWatch en 2026-11-04T21:15:36.000Z X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/CDRE/cadre-holdings-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:15:00.000Z Cadre Holdings Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EW/edwards-lifesciences-q3-results-2026 BiopharmaWatch en 2026-11-04T21:15:00.000Z Edwards Lifesciences Reports Third Quarter Results https://www.biopharmawatch.com/news/BIO/bio-rad-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:15:00.000Z Bio-Rad Reports Third-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ARDT/ardent-health-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:15:00.000Z Ardent Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/EHTH/ehealth-announces-q3-2026-results BiopharmaWatch en 2026-11-04T21:15:00.000Z eHealth, Inc. Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/MMED/minimed-fiscal-year-2027-q2-results BiopharmaWatch en 2026-11-04T21:15:00.000Z MiniMed to Announce Its Fiscal Year 2027 Second Quarter Financial Results https://www.biopharmawatch.com/news/MDT/medtronic-q2-fiscal-year-2027-results BiopharmaWatch en 2026-11-04T21:15:00.000Z Medtronic to announce financial results for its second quarter of fiscal year 2027 https://www.biopharmawatch.com/news/VOR/vor-bio-reports-inducement-grant-nasdaq-listing-rule-5635-c-20261104 BiopharmaWatch en 2026-11-04T21:15:00.000Z Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BTMD/biote-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:11:00.000Z Biote Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MCK/mckesson-fiscal-2027-q2-results-guidance BiopharmaWatch en 2026-11-04T21:10:00.000Z McKesson Reports Fiscal 2027 Second Quarter Results and Raises Full Year Adjusted EPS Guidance https://www.biopharmawatch.com/news/ANVS/annovis-launch-public-offering BiopharmaWatch en 2026-11-04T21:07:00.000Z Annovis Announces Launch of Proposed Public Offering https://www.biopharmawatch.com/news/SLDB/solid-biosciences-q3-2026-results-business-updates BiopharmaWatch en 2026-11-04T21:07:00.000Z Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T21:06:00.000Z Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/AGMB/agomab-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T21:05:47.000Z Agomab to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:46.000Z Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PRCT/procept-biorobotics-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:42.000Z PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance https://www.biopharmawatch.com/news/VCYT/veracyte-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:37.000Z Veracyte Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NATR/natures-sunshine-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Nature's Sunshine Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/ACAD/acadia-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EOLS/evolus-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook https://www.biopharmawatch.com/news/QGEN/qiagen-reports-full-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z QIAGEN Reports Full Q3 2026 Results https://www.biopharmawatch.com/news/KRMD/koru-medical-investor-conference-participation BiopharmaWatch en 2026-11-04T21:05:00.000Z KORU Medical Systems to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AHCO/adapthealth-participate-ubs-conference BiopharmaWatch en 2026-11-04T21:05:00.000Z AdaptHealth Corp. to Participate in Upcoming Investor Conference https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-q3-2026-results-financial-guidance BiopharmaWatch en 2026-11-04T21:05:00.000Z Acadia Healthcare Announces Third Quarter 2026 Results and Raises Full Year 2026 Financial Guidance https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-bio-thrax-supply-order BiopharmaWatch en 2026-11-04T21:05:00.000Z Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War https://www.biopharmawatch.com/news/VIR/vir-biotechnology-corporate-update-q3-2026 BiopharmaWatch en 2026-11-04T21:05:00.000Z Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AGL/agilon-health-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z agilon health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/SDGR/schrodinger-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Schrödinger Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/INVA/innoviva-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-q3-2026-results-pipeline-update BiopharmaWatch en 2026-11-04T21:05:00.000Z Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update https://www.biopharmawatch.com/news/ARAY/accuray-fiscal-2027-first-quarter-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Accuray Reports Fiscal 2027 First Quarter Financial Results https://www.biopharmawatch.com/news/PGEN/precigen-reports-q3-2026-results-papzimeos-revenue-growth BiopharmaWatch en 2026-11-04T21:05:00.000Z Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance https://www.biopharmawatch.com/news/SERA/sera-prognostics-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/NVST/envista-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Envista Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/CAI/caris-life-sciences-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance https://www.biopharmawatch.com/news/NUVB/nuvation-bio-q3-2026-financial-results-update BiopharmaWatch en 2026-11-04T21:05:00.000Z Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LMAT/lemaitre-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z LeMaitre Q3 2026 Financial Results https://www.biopharmawatch.com/news/SGHT/sight-sciences-reports-third-quarter-2026-financial-results-raises-full BiopharmaWatch en 2026-11-04T21:05:00.000Z Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives https://www.biopharmawatch.com/news/PACB/pacbio-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z PacBio Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PCVX/vaxcyte-reports-q3-2026-results-and-update BiopharmaWatch en 2026-11-04T21:05:00.000Z Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CLOV/clover-health-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Clover Health Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/LRMR/larimar-therapeutics-guggenheim-conference-2026 BiopharmaWatch en 2026-11-04T21:05:00.000Z Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates https://www.biopharmawatch.com/news/MDCX/medicus-pharma-q3-2026-update-call BiopharmaWatch en 2026-11-04T21:05:00.000Z Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026 https://www.biopharmawatch.com/news/BLLN/billiontoone-reports-q3-2026-results-guidance BiopharmaWatch en 2026-11-04T21:05:00.000Z BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance https://www.biopharmawatch.com/news/ADMA/adma-biologics-reports-third-quarter-2026-financial-results-provides-business BiopharmaWatch en 2026-11-04T21:05:00.000Z ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q3-2026-results-call BiopharmaWatch en 2026-11-04T21:05:00.000Z Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026 https://www.biopharmawatch.com/news/PNTG/pennant-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Pennant Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-q3-2026-results-business-highlights BiopharmaWatch en 2026-11-04T21:05:00.000Z OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights https://www.biopharmawatch.com/news/ECOR/electrocore-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z electroCore Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-announces-inducement-grant-nasdaq-listing-rule-5635-c-20261104 BiopharmaWatch en 2026-11-04T21:05:00.000Z Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-q3-2026-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026 https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-04T21:05:00.000Z Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/IMRX/immuneering-presents-guggenheim-healthcare-innovation-conference BiopharmaWatch en 2026-11-04T21:05:00.000Z Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-04T21:05:00.000Z Cytek Biosciences Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-investor-conferences-2026 BiopharmaWatch en 2026-11-04T21:05:00.000Z Alamar Biosciences to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/KLRA/kailera-reports-q3-2026-results-business-updates BiopharmaWatch en 2026-11-04T21:05:00.000Z Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:02:47.000Z Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:02:00.000Z Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BDMD/baird-medical-statement-share-price-volatility BiopharmaWatch en 2026-11-04T21:02:00.000Z Baird Medical Issues Statement Regarding Recent Share Price Volatility https://www.biopharmawatch.com/news/GRAL/grail-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:02:00.000Z GRAIL Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TKNO/teknova-reports-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-04T21:01:49.000Z Teknova Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TKNO/teknova-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T21:01:49.000Z Teknova Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/STAA/staar-surgical-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:01:00.000Z STAAR Surgical Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/PSNL/personalis-reports-third-quarter-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Personalis Reports Third Quarter Results https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-q3-2026-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Maravai LifeSciences Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/XNCR/xencor-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Xencor Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMCC/im-cannabis-raises-us1200000-convertible-note-financing BiopharmaWatch en 2026-11-04T21:01:00.000Z IM Cannabis Raises US$1,200,000 of Gross Proceeds in Convertible Note Financing https://www.biopharmawatch.com/news/EWTX/edgewise-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Edgewise Therapeutics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OLMA/olema-oncology-presents-combination-data-sabcs-2026 BiopharmaWatch en 2026-11-04T21:01:00.000Z Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium https://www.biopharmawatch.com/news/ARVN/arvinas-arv-393-ash-2026-presentation BiopharmaWatch en 2026-11-04T21:01:00.000Z Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting https://www.biopharmawatch.com/news/BDMD/baird-medical-nasdaq-notification-minimum-bid-price BiopharmaWatch en 2026-11-04T21:01:00.000Z Baird Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency https://www.biopharmawatch.com/news/CABA/cabaletta-bio-reports-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-11-04T21:01:00.000Z Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CLDX/celldex-investor-conferences-november-december-2026 BiopharmaWatch en 2026-11-04T21:01:00.000Z Celldex to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/DSGN/design-therapeutics-q3-2026-results-updates BiopharmaWatch en 2026-11-04T21:01:00.000Z Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-nasdaq-listing-rule-20261104 BiopharmaWatch en 2026-11-04T21:01:00.000Z Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/OM/outset-medical-reports-q3-2026-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Outset Medical Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T21:01:00.000Z Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results https://www.biopharmawatch.com/news/BCRX/biocryst-present-investor-conferences BiopharmaWatch en 2026-11-04T21:01:00.000Z BioCryst to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261104 BiopharmaWatch en 2026-11-04T21:01:00.000Z Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-04T21:00:00.000Z AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/VRTX/vertex-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T21:00:00.000Z Vertex to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ARQT/arcutis-q3-2026-financial-results-update BiopharmaWatch en 2026-11-04T21:00:00.000Z Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CYTK/cytokinetics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-04T21:00:00.000Z Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-quality-of-life-data-eortc-cltg-2026 BiopharmaWatch en 2026-11-04T18:45:00.000Z Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe https://www.biopharmawatch.com/news/DH/definitive-healthcare-executive-appointments-ai-initiatives BiopharmaWatch en 2026-11-04T18:14:15.000Z Definitive Healthcare announces executive appointments to bolster AI-powered initiatives across the company https://www.biopharmawatch.com/news/SNY/sanofi-ranked-first-2026-digital-innovation-index BiopharmaWatch en 2026-11-04T17:00:00.000Z CNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation Index https://www.biopharmawatch.com/news/VALN/valneva-nine-month-2026-financial-results-report BiopharmaWatch en 2026-11-04T16:45:00.000Z Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026 https://www.biopharmawatch.com/news/MRNA/moderna-bundibugyo-ebola-vaccine-phase-2-3-study BiopharmaWatch en 2026-11-04T16:05:00.000Z Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study https://www.biopharmawatch.com/news/MBRX/moleculin-announces-annamycin-presentation-ash-2026 BiopharmaWatch en 2026-11-04T16:00:00.000Z Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/MRNA/moderna-mrna-2808-clinical-data-ash-2026 BiopharmaWatch en 2026-11-04T14:50:00.000Z Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting https://www.biopharmawatch.com/news/ONCY/pelareorep-hpv-immune-responses-anal-cancer BiopharmaWatch en 2026-11-04T14:30:00.000Z Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-autumn-leaves-melanoma-awareness BiopharmaWatch en 2026-11-04T14:27:00.000Z Bristol Myers Squibb Canada Partners with TANK Worldwide and Ogilvy Health to Turn Autumn Leaves into a Guide for Spotting the Warning Signs of Melanoma https://www.biopharmawatch.com/news/COSM/cosmos-health-amazon-uk-sales-growth BiopharmaWatch en 2026-11-04T14:27:00.000Z Cosmos Health's Amazon UK Business Surpasses $2 Million in TTM Sales, Up 90%, with a 23% Net Profit Margin; Expects Sales to Grow Approximately 72% to $3.9 Million Over the Next Twelve Months https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-mgx-001-ash-presentation BiopharmaWatch en 2026-11-04T14:25:00.000Z Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-ash-presentation-dnase-i BiopharmaWatch en 2026-11-04T14:20:00.000Z Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-clinical-data-updates-ash-2026 BiopharmaWatch en 2026-11-04T14:15:00.000Z Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026 https://www.biopharmawatch.com/news/GILD/gilead-kite-ash-2026-presentations BiopharmaWatch en 2026-11-04T14:15:00.000Z Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026 https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-ash-annual-meeting-presentations BiopharmaWatch en 2026-11-04T14:15:00.000Z TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition https://www.biopharmawatch.com/news/RIGL/rigel-phase-1b-data-r289-mds-ash-meeting BiopharmaWatch en 2026-11-04T14:15:00.000Z Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition https://www.biopharmawatch.com/news/IMMX/immix-biopharma-nxc-201-ash-2026-presentation BiopharmaWatch en 2026-11-04T14:15:00.000Z Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026 https://www.biopharmawatch.com/news/BNTX/penn-biontech-seed-fund-invests-emvena-therapeutics BiopharmaWatch en 2026-11-04T14:14:00.000Z Penn-BioNTech Innovative Therapeutics Seed Fund Announces First Investment https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-ash-2026-presentations BiopharmaWatch en 2026-11-04T14:14:00.000Z Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting https://www.biopharmawatch.com/news/ONC/fda-priority-review-brukinsa-mcl BiopharmaWatch en 2026-11-04T14:13:00.000Z U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma https://www.biopharmawatch.com/news/A/agilent-completes-acquisition-of-proscia BiopharmaWatch en 2026-11-04T14:12:00.000Z Agilent Completes Acquisition of Proscia https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-ash-2026-iomab-act-results BiopharmaWatch en 2026-11-04T14:11:00.000Z Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-ash-2026-actimab-a-results BiopharmaWatch en 2026-11-04T14:05:00.000Z Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-ash-meeting-2026 BiopharmaWatch en 2026-11-04T14:05:00.000Z Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition https://www.biopharmawatch.com/news/DARE/dare-bioscience-presentation-stifel-2026-conference BiopharmaWatch en 2026-11-04T14:05:00.000Z Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference https://www.biopharmawatch.com/news/IRON/disc-medicine-ash-annual-meeting-2026 BiopharmaWatch en 2026-11-04T14:05:00.000Z Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/LEXX/lexaria-new-pharmaceutical-agreement-dehydratech BiopharmaWatch en 2026-11-04T14:04:24.000Z Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-80-million-private-placement BiopharmaWatch en 2026-11-04T14:02:00.000Z Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission https://www.biopharmawatch.com/news/KURA/kura-kyowa-ziftomenib-data-ash-2026 BiopharmaWatch en 2026-11-04T14:02:00.000Z Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026 https://www.biopharmawatch.com/news/IMNM/immunome-first-in-human-data-im-1021-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026 https://www.biopharmawatch.com/news/KPTI/karyopharm-selinexor-data-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH) https://www.biopharmawatch.com/news/CRVS/corvus-soquelitinib-alps-trial-data-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition https://www.biopharmawatch.com/news/SNDX/syndax-host-ash-investor-event-december-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026 https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-ronde-cel-data-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma https://www.biopharmawatch.com/news/AGIO/agios-new-clinical-data-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026 https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-zugo-cel-ash-meeting-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition https://www.biopharmawatch.com/news/LKFT/lakefront-biotherapeutics-poster-presentation-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-beacon-trial-ash-presentation BiopharmaWatch en 2026-11-04T14:00:42.000Z Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-ash-2026-presentations BiopharmaWatch en 2026-11-04T14:00:39.000Z Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/AMLX/amylyx-investor-event-obesityweek-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts https://www.biopharmawatch.com/news/EVAX/evaxion-evx-04-ash-2026-presentation BiopharmaWatch en 2026-11-04T14:00:00.000Z Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting https://www.biopharmawatch.com/news/SLN/silence-therapeutics-divesiran-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026 https://www.biopharmawatch.com/news/INCY/incyte-new-data-hematology-portfolio-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026 https://www.biopharmawatch.com/news/BMRN/biomarin-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T14:00:00.000Z BioMarin to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ADCT/adct-zynlonta-ash-annual-meeting-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program https://www.biopharmawatch.com/news/GERN/geron-rytelos-data-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026 https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-positive-phase-2-data-sls009 BiopharmaWatch en 2026-11-04T14:00:00.000Z SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026 https://www.biopharmawatch.com/news/SNDX/syndax-ash-2026-abstracts-revumenib-axatilimab BiopharmaWatch en 2026-11-04T14:00:00.000Z Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026 https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-ash-presentation-iopofosine BiopharmaWatch en 2026-11-04T14:00:00.000Z Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-dmr-001-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026 https://www.biopharmawatch.com/news/CLYM/climb-bio-budoprutug-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition https://www.biopharmawatch.com/news/GMAB/genmab-epcoritamab-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-canaccord-genuity-forum-participation BiopharmaWatch en 2026-11-04T13:55:00.000Z Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum https://www.biopharmawatch.com/news/ONMD/onemednet-mid-six-figure-reorder-radiology-models BiopharmaWatch en 2026-11-04T13:45:00.000Z OneMedNet Receives Mid Six-Figure Re-Order from Foundation Model Company Developing Radiology Models https://www.biopharmawatch.com/news/ICU/seastar-medical-q3-results-november-2026 BiopharmaWatch en 2026-11-04T13:41:00.000Z SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026 https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ovarian-cancer-car-t-trial-esmo-2026 BiopharmaWatch en 2026-11-04T13:35:00.000Z Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026 https://www.biopharmawatch.com/news/LH/labcorp-acquisition-millennium-health BiopharmaWatch en 2026-11-04T13:30:00.000Z Labcorp Completes Acquisition of Millennium Health https://www.biopharmawatch.com/news/TLPH/talphera-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-04T13:30:00.000Z Talphera to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026 https://www.biopharmawatch.com/news/ERAS/tango-erasca-phase-1-2-study-vopimetostat-eras-0015 BiopharmaWatch en 2026-11-04T13:30:00.000Z Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T13:30:00.000Z Aprea Therapeutics Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MDCX/medicus-pharma-skinject-business-combination BiopharmaWatch en 2026-11-04T13:30:00.000Z Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-webull-biotech-webinar BiopharmaWatch en 2026-11-04T13:30:00.000Z Intelligent Bio Solutions to Present at the Webull Biotech Webinar on November 12 https://www.biopharmawatch.com/news/CLNN/clene-reports-q3-2026-results-and-highlights BiopharmaWatch en 2026-11-04T13:30:00.000Z Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261104 BiopharmaWatch en 2026-11-04T13:30:00.000Z Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/HYFT/mindwalk-teva-australia-antibody-discovery-agreement BiopharmaWatch en 2026-11-04T13:01:00.000Z MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows https://www.biopharmawatch.com/news/PMVP/rezatapopt-pynnacle-data-ena-2026 BiopharmaWatch en 2026-11-04T13:00:37.000Z Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026 https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-04T13:00:00.000Z Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/UNH/unitedhealth-group-board-authorizes-payment-quarterly-dividend BiopharmaWatch en 2026-11-04T13:00:00.000Z UnitedHealth Group Board Authorizes Payment of Quarterly Dividend https://www.biopharmawatch.com/news/INCY/incyte-present-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T13:00:00.000Z Incyte to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/IBRX/immunitybio-first-patients-europe-anktiva-bcg BiopharmaWatch en 2026-11-04T13:00:00.000Z ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-eb-003-qeeg-study-results BiopharmaWatch en 2026-11-04T13:00:00.000Z Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study https://www.biopharmawatch.com/news/LH/labcorp-speak-ubs-global-healthcare-conference BiopharmaWatch en 2026-11-04T13:00:00.000Z Labcorp to Speak at the UBS Global Healthcare Conference https://www.biopharmawatch.com/news/MDT/medtronic-michael-j-fox-foundation-parkinson-dbs-education BiopharmaWatch en 2026-11-04T13:00:00.000Z Medtronic and Michael J. Fox Foundation Partner to Help More People with Parkinson's Understand Deep Brain Stimulation https://www.biopharmawatch.com/news/ETRA/electra-therapeutics-presentation-jefferies-conference-2026 BiopharmaWatch en 2026-11-04T13:00:00.000Z Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-kol-event-november-2026 BiopharmaWatch en 2026-11-04T13:00:00.000Z Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC https://www.biopharmawatch.com/news/NTLA/intellia-completes-enrollment-magnitude-2-trial-nex-z BiopharmaWatch en 2026-11-04T13:00:00.000Z Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN) https://www.biopharmawatch.com/news/CLGN/collplant-name-change-optiphi-computing BiopharmaWatch en 2026-11-04T13:00:00.000Z CollPlant Announces Proposed Name Change to OptiPhi Computing Reflecting Expansion to Computing with Light https://www.biopharmawatch.com/news/SCTX/scribe-therapeutics-presents-data-aha-scientific-sessions-2026 BiopharmaWatch en 2026-11-04T13:00:00.000Z Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026 https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-preclinical-data-ena-2026 BiopharmaWatch en 2026-11-04T13:00:00.000Z Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026 https://www.biopharmawatch.com/news/URGN/urogen-reports-zusduri-revenue-q3-2026 BiopharmaWatch en 2026-11-04T13:00:00.000Z UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights https://www.biopharmawatch.com/news/BIVI/biovie-announces-4-74-million-offering BiopharmaWatch en 2026-11-04T13:00:00.000Z BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reverse-stock-split BiopharmaWatch en 2026-11-04T13:00:00.000Z Jasper Therapeutics Announces 1-for-30 Reverse Stock Split https://www.biopharmawatch.com/news/SEPN/septerna-selects-sep-204-for-graves-disease-and-ted BiopharmaWatch en 2026-11-04T13:00:00.000Z Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting https://www.biopharmawatch.com/news/STRO/sutro-biopharma-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T13:00:00.000Z Sutro Biopharma to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-leadership-appointments BiopharmaWatch en 2026-11-04T13:00:00.000Z Processa Pharmaceuticals Announces Key Leadership Appointments https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-november-investor-conferences BiopharmaWatch en 2026-11-04T13:00:00.000Z Phathom Pharmaceuticals to Participate in November Investor Conferences https://www.biopharmawatch.com/news/NCEL/newcelx-divests-mazindol-portfolio-to-rea-holdings BiopharmaWatch en 2026-11-04T13:00:00.000Z NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments https://www.biopharmawatch.com/news/RYTM/nice-guidance-imcivree-bardet-biedl-syndrome BiopharmaWatch en 2026-11-04T13:00:00.000Z Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome https://www.biopharmawatch.com/news/STIM/neuronetics-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:50:00.000Z Neuronetics Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-refinances-credit-facility BiopharmaWatch en 2026-11-04T12:30:00.000Z Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity https://www.biopharmawatch.com/news/DRIO/dariohealth-appoints-john-palumbo-chairman-board BiopharmaWatch en 2026-11-04T12:30:00.000Z Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care https://www.biopharmawatch.com/news/IMRX/immuneering-atebimetinib-potential-combinations-cancers BiopharmaWatch en 2026-11-04T12:30:00.000Z Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/MDLN/medline-reports-third-quarter-nine-months-2026-results BiopharmaWatch en 2026-11-04T12:30:00.000Z Medline Reports Third Quarter and Nine Months 2026 Results https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-corporate-update-q3-results BiopharmaWatch en 2026-11-04T12:30:00.000Z NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results https://www.biopharmawatch.com/news/CNSY/cerenome-aetna-cnside-agreement BiopharmaWatch en 2026-11-04T12:30:00.000Z Cerenome Secures National In-Network Agreement with Aetna for CNSide® https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-jefferies-conference-2026 BiopharmaWatch en 2026-11-04T12:30:00.000Z Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-canaccord-genuity-forum-2026 BiopharmaWatch en 2026-11-04T12:30:00.000Z Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-q3-2026-results-bp-205-data BiopharmaWatch en 2026-11-04T12:30:00.000Z Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-guggenheim-conference-2026 BiopharmaWatch en 2026-11-04T12:05:00.000Z Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:05:00.000Z Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update https://www.biopharmawatch.com/news/QURE/uniqure-q3-2026-financial-results-update BiopharmaWatch en 2026-11-04T12:05:00.000Z uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update https://www.biopharmawatch.com/news/RPRX/royalty-pharma-q3-2026-results BiopharmaWatch en 2026-11-04T12:03:28.000Z Royalty Pharma reports third quarter 2026 results https://www.biopharmawatch.com/news/GERN/geron-corporation-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:03:00.000Z Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T12:01:00.000Z Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-q3-2026-results BiopharmaWatch en 2026-11-04T12:00:00.000Z Charles River Laboratories Announces Third-Quarter 2026 Results https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-investor-conferences-2026 BiopharmaWatch en 2026-11-04T12:00:00.000Z Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T12:00:00.000Z Insulet Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/NTRA/signatera-head-neck-cancer-publications BiopharmaWatch en 2026-11-04T12:00:00.000Z Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability https://www.biopharmawatch.com/news/MASS/908-devices-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-04T12:00:00.000Z 908 Devices to Participate in the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-nominates-an2-504661-hpp BiopharmaWatch en 2026-11-04T12:00:00.000Z AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP) https://www.biopharmawatch.com/news/BRKR/bruker-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:00:00.000Z Bruker Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/UTHR/united-therapeutics-buys-down-ralinepag-royalty BiopharmaWatch en 2026-11-04T12:00:00.000Z United Therapeutics Announces Buydown of Ralinepag Royalty https://www.biopharmawatch.com/news/INSM/insmed-investor-conferences-november-december-2026 BiopharmaWatch en 2026-11-04T12:00:00.000Z Insmed to Present at November and December 2026 Investor Conferences https://www.biopharmawatch.com/news/GNPX/genprex-trop2-predictive-biomarker-lung-cancer BiopharmaWatch en 2026-11-04T12:00:00.000Z Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-bh-30236-ash-presentation BiopharmaWatch en 2026-11-04T12:00:00.000Z BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-04T12:00:00.000Z Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-ser-155-ir-ec-development BiopharmaWatch en 2026-11-04T12:00:00.000Z Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-04T12:00:00.000Z Ocugen Provides Business Update with Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-04T12:00:00.000Z Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/BCRX/biocryst-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:00:00.000Z BioCryst Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-q3-2026-results-highlights BiopharmaWatch en 2026-11-04T12:00:00.000Z Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-jefferies-conference-2026 BiopharmaWatch en 2026-11-04T12:00:00.000Z Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/OPCH/option-care-health-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:00:00.000Z Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/RGEN/repligen-corporation-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-04T12:00:00.000Z Repligen Corporation to Present at Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-fda-alignment-rad101-trial BiopharmaWatch en 2026-11-04T12:00:00.000Z Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases https://www.biopharmawatch.com/news/ACIU/ac-immune-q3-2026-financial-update BiopharmaWatch en 2026-11-04T12:00:00.000Z AC Immune Third Quarter 2026 Financial and Corporate Update https://www.biopharmawatch.com/news/MLTX/moonlake-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-04T12:00:00.000Z MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-guggenheim-healthcare-conference BiopharmaWatch en 2026-11-04T12:00:00.000Z Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-guggenheim-conference-2026 BiopharmaWatch en 2026-11-04T12:00:00.000Z Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-dt120-phase-3-data-nei-fall-congress BiopharmaWatch en 2026-11-04T12:00:00.000Z Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress https://www.biopharmawatch.com/news/VTRS/viatris-announces-quarterly-dividend-20261104 BiopharmaWatch en 2026-11-04T11:59:00.000Z Viatris Announces Quarterly Dividend https://www.biopharmawatch.com/news/QTTB/q32-bio-reports-q3-2026-results-corporate-update BiopharmaWatch en 2026-11-04T11:59:00.000Z Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-employee-inducement-grants BiopharmaWatch en 2026-11-04T11:57:00.000Z Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 https://www.biopharmawatch.com/news/BDX/bd-names-bridget-bagnato-president-peripheral-intervention BiopharmaWatch en 2026-11-04T11:50:00.000Z BD Names Bridget Bagnato Worldwide President of Peripheral Intervention https://www.biopharmawatch.com/news/COR/cencora-fiscal-2026-fourth-quarter-results BiopharmaWatch en 2026-11-04T11:35:00.000Z Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results https://www.biopharmawatch.com/news/COR/cencora-new-organizational-structure BiopharmaWatch en 2026-11-04T11:35:00.000Z Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus https://www.biopharmawatch.com/news/CVS/cvs-health-separation-into-two-companies BiopharmaWatch en 2026-11-04T11:31:00.000Z CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare https://www.biopharmawatch.com/news/UTHR/united-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T11:30:00.000Z United Therapeutics Corporation Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CMPS/compass-pathways-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-04T11:30:00.000Z Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th https://www.biopharmawatch.com/news/PRGO/perrigo-third-quarter-2026-results BiopharmaWatch en 2026-11-04T11:30:00.000Z Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations https://www.biopharmawatch.com/news/CVS/cvs-health-reports-q3-2026-results BiopharmaWatch en 2026-11-04T11:30:00.000Z CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-third-quarter-2026-results BiopharmaWatch en 2026-11-04T11:30:00.000Z Zimmer Biomet Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/blog/big-pharma-q3-2026-earnings-ranked BiopharmaWatch en 2026-11-04T11:00:06.527Z Big Pharma Q3 2026 Earnings Ranked: Lilly Takes the Growth https://www.biopharmawatch.com/news/LIVN/livanova-reports-q3-2026-results-guidance-raise BiopharmaWatch en 2026-11-04T11:00:00.000Z LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-november-2026-investor-events BiopharmaWatch en 2026-11-04T11:00:00.000Z IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events https://www.biopharmawatch.com/news/WST/west-participate-upcoming-investor-conference BiopharmaWatch en 2026-11-04T11:00:00.000Z West to Participate in Upcoming Investor Conference https://www.biopharmawatch.com/news/BDSX/biodesix-participate-upcoming-investor-conferences-20261104 BiopharmaWatch en 2026-11-04T11:00:00.000Z Biodesix to Participate in Upcoming Investor Conferences